Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: J Glob Antimicrob Resist. 2015 Dec 21;5:57–61. doi: 10.1016/j.jgar.2015.12.002

Table 3.

Clinical outcomes by treatment classification for non-faecium, non-faecalis vancomycin-resistant enterococcal bloodstream infections (VRE BSIs)

Outcome RR (95% CI) P-value
Treatment failure 2.62 (1.03–6.65) 0.019
 30-day all-cause mortality 1.51 (0.50–4.54) 0.380
 Microbiological failure a 1.76 (1.18–2.62) 0.030
 30-day VRE BSI recurrence 1.95 (1.45–2.63) 0.032
Hospital mortality 1.20 (0.57–2.51) 0.600

RR, risk ratio; CI, confidence interval.

Reference group: β-lactam treatment.

a

Percentages among those with at least one follow-up blood culture drawn during treatment period.